Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0TA8O
|
|||
| Drug Name |
LTT462
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Phase 1 | [1] | |
| Company |
Novartis Oncology East Hanover, NJ
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mitogen-activated protein kinase (MAPK) | Target Info | Inhibitor | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.